Researchers have taken an extraordinary step toward “photosynthetic” medicine by transplanting plant light-harvesting machinery into mammalian eye cells, enabling the cornea to generate its own light-driven metabolic fuel. Published in Cell, the study introduces a chloroplast-derived nanosystem dubbed LEAF (light-harvesting augmentation factor), which the authors say can suppress oxidative stress and inflammation in the eye using ordinary visible light.
The work, led by investigators in China, Singapore, and the US, explores whether mammalian tissues could borrow one of biology’s oldest energy systems: photosynthesis. While visible light enables vision in humans, plants use the same wavelengths to power metabolic reactions through chloroplast thylakoids. The researchers wondered whether those reactions could be partially transplanted into mammalian cells.
Their solution was LEAF, a nanoscale structure derived from spinach chloroplast thylakoid grana. Rather than attempting to transfer whole chloroplasts, the team isolated and stabilized the membrane supercomplexes responsible for the light-dependent reactions of photosynthesis. Once introduced into mammalian corneal cells, LEAF acted as a temporary neo-organelle, producing nicotinamide adenine dinucleotide phosphate (NADPH) and ATP when exposed to light.
The implications are potentially significant for ocular surface disease. Oxidative stress and inflammatory signaling are central drivers of disorders such as dry eye disease, chemical injury, and corneal inflammation. NADPH is critical for antioxidant defense systems, yet endogenous production can become depleted during inflammation.
The investigators showed that LEAF-generated NADPH functioned independently of mammalian metabolic pathways. Even when native NADPH synthesis was pharmacologically blocked, illuminated LEAF restored intracellular NADPH levels and reduced reactive oxygen species in cultured cells. Metabolomic analyses further suggested that treated cells shifted away from a pro-inflammatory state toward a more balanced metabolic profile.
The cornea proved especially well-suited to this approach. Because the ocular surface is naturally exposed to ambient visible light, no external activation device was required, and the authors note that ordinary waking-hour light entering the eye is sufficient to drive the light-dependent photosynthetic reactions.
In mouse models of corneal inflammation, LEAF treatment reduced inflammatory markers and oxidative damage while improving tissue recovery. The nanoscale particles were also efficiently internalized by corneal epithelial cells and macrophages, enabling both intracellular and extracellular antioxidant effects.
The concept draws inspiration from nature. Sacoglossan sea slugs can temporarily retain functional chloroplasts from algae, allowing them to derive metabolic benefit from photosynthesis. The study authors describe LEAF as a “cross-kingdom, endosymbiosis-like interaction” between plant-derived organelles and mammalian tissue.
Still, significant hurdles remain before clinical translation becomes realistic. The long-term persistence, immunologic safety, and scalability of plant-derived photosynthetic systems in humans remain unknown. The therapy’s durability and regulatory pathway are also likely to prove challenging.
The study represents one of the more imaginative examples of bioengineered ocular therapy in recent years. Rather than simply delivering drugs to suppress inflammation, the researchers propose using light itself as a metabolic energy source for the eye. If future studies validate the concept in larger models and human tissues, ophthalmology may one day gain a therapeutic strategy that sounds closer to science fiction than conventional pharmacology: photosynthesis in the human eye.
